Purpose of the development: For quick stop of massive bleeding; with bleeding in patients with hemophilia; with bleeding in patients in the presence of anticoagulants.

Recommended application field: The medicine. Wounded in war and in the home, patients with bleeding surgical and burn departments of civilian and military clinical institutions, emergency medical care.

Advantages over analogues: Provides: - effective stopping of massive bleeding, surpassing world analogues: the level of blood loss when using a hemostatic combined agent is less than in the case of using effective world analogues - "CELOX" (EU) and "QuikСlot" (USA) - rapid stop of bleeding in patients with hemophilia; - antiedematous, anti-inflammatory, analgesic and antimicrobial action; - designed for use both in the clinic and in the field and in everyday life, as part of individual first-aid kits of various profiles.

The development stage readiness: tested in laboratory condition

Description of the development:
()
Developed: an effective hemostatic combined agent for stopping massive bleeding, including hemophilia, which combines the powerful hemostatic potential of a blood clotting activator and the sorption properties of highly activated carbon materials for medical purposes.

Information about newness of the development:
there are Ukrainian patents -- 2 items

corresponds technical description
Guarantees stable results getting

Possibility of transfer abroad:
Combinated reduction to industrial level

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua